It is also tempting to speculate that endogenous circulating anti-SEB Abs may contribute to the age-related protection against severe COVID disease; titers of antibodies against SEB are known to decrease after 70 years (59, 60), and that population is more susceptible to develop severe COVID-19. Here, SETBP1 is linked to COVID-19.